Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 3 4Phase 1 3Phase 1/2 2

Status

Recruiting 1Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 59Thoracic 34Other hematologic neoplasm 31Sarcoma 6Genitourinary 4Other solid neoplasm 3Gynecologic 3CNS 3Myeloid 2Endocrine 2Dermatologic 2Classical hematology 2Breast 1

Conditions

Carcinoma, Neuroendocrine 2Small Cell Lung Carcinoma 1Carcinoma, Small Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

lutetium Lu 177 dotatate 5surufatinib 4gallium Ga 68 dotatate 4Nivolumab 4Cisplatin 4pembrolizumab 3atezolizumab 3Everolimus 3selpercatinib 2olaparib 2lanreotide 2avelumab 2Radiotherapy 2Paclitaxel 2Etoposide 23-Iodobenzylguanidine 2veliparib 1vandetanib 1tivozanib 1tislelizumab 1spartalizumab 1sapanisertib 1repotrectinib 1regorafenib 1pralsetinib 1pegfilgrastim 1irinotecan sucrosofate 1iodophenyl metomidate 1fosbretabulin 1entrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Etoposide × Endocrine × Clear all
NCT06372626 2024-06-14

Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 1/2 Recruiting
93 enrolled
Endocrine

Carcinoma, Neuroendocrine

NCT01642251 2023-05-06

Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
156 enrolled 13 charts
EndocrineThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Neuroendocrine, Carcinoma, Small Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡